Publication: Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)
Issued Date
2020-09-01
Resource Type
ISSN
17912423
10196439
10196439
Other identifier(s)
2-s2.0-85088095516
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Oncology. Vol.57, No.3 (2020), 678-696
Suggested Citation
Wararat Chiangjong, Somchai Chutipongtanate, Suradej Hongeng Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review). International Journal of Oncology. Vol.57, No.3 (2020), 678-696. doi:10.3892/ijo.2020.5099 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/57679
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)
Other Contributor(s)
Abstract
© This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. Cancer is currently ineffectively treated using therapeutic drugs, and is also able to resist drug action, resulting in increased side effects following drug treatment. A novel therapeutic strategy against cancer cells is the use of anticancer peptides (ACPs). The physicochemical properties, amino acid composition and the addition of chemical groups on the ACP sequence influences their conformation, net charge and orientation of the secondary structure, leading to an effect on targeting specificity and ACP-cell interaction, as well as peptide penetrating capability, stability and efficacy. ACPs have been developed from both naturally occurring and modified peptides by substituting neutral or anionic amino acid residues with cationic amino acid residues, or by adding a chemical group. The modified peptides lead to an increase in the effectiveness of cancer therapy. Due to this effectiveness, ACPs have recently been improved to form drugs and vaccines, which have sequentially been evaluated in various phases of clinical trials. The development of the ACPs remains focused on generating newly modified ACPs for clinical application in order to decrease the incidence of new cancer cases and decrease the mortality rate. The present review could further facilitate the design of ACPs and increase efficacious ACP therapy in the near future.